Up to 30% of people with psoriasis also develop psoriatic arthritis (PsA). PsA is a form of arthritis specifically associated with psoriasis of the skin, which causes pain, stiffness and swelling in and around the joints. Genetic predisposition, the immune system and environmental factors are all believed to play a role in the onset of PsA. Without treatment, this chronic, debilitating disease can be life-altering.

With biologics, such as Enbrel® (Amgen/Pfizer) and Humira (AbbVie), the Psoriatic Arthritis market has experienced strong growth over the past few years. In addition, the cost of these therapies has driven the market to the $1 billion+ level. Psoriatic Arthritis Market Info™ from Drug Market Info captures explicit data on this disorder, which is often difficult to extract because PsA data tends to be “lumped” or buried within data for rheumatoid arthritis or psoriasis. Psoriatic Arthritis Market Info™ is unique in that it focuses only on this condition.

A key issue for psoriatic arthritis management is correct diagnosis so that disease-modifying therapy can begin as quickly as possible. Yet it can take years for the condition to be accurately diagnosed. Learn why in Psoriatic Arthritis Market Info™ which also provides Patient Perspectives and how patients deal with this disease. Actual patient verbatims are included in all Drug Market Info reports. The report covers how PsA starts, how it is diagnosed, and how it is managed, especially when concurrent with skin disease.

Other benefits of Psoriatic Arthritis Info™ you won’t find in other reports include…

• A presentation-ready format: 
  The report is presented entirely on PowerPoint slides to make reading and data assimulation easier, quicker and ready to cut and paste into your own reports/presentations
• Five years of sales and prescription data:
  Pharmaceutical audit data provides an estimate of the actual market value, along with growth trends and analyses by therapeutic modality as well as by brand
• Thought Leader Review:
  All Drug Market Info reports are reviewed by and incorporate the insights of a leading thought leader in the field to ensure clinical accuracy and relevancy from a doctor’s perspective. Elaine Husni, MD, Department Vice Chair of Rheumatology and Director of the Arthritis and Musculoskeletal Treatment Center at the Cleveland Clinic reviewed this report. Dr. Husni is the recipient of several research awards, is involved in a number of clinical trials and is the Director of Clinical Outcomes Research.

If you want to better understand how the psoriasis and PsA markets overlap, Drug Market Info also offers a companion report, Psoriasis Market Info™, which incorporates all of the relevant data on the cutaneous disease. Both reports, Psoriasis Market Info™ and Psoriatic Arthritis Market Info™ can be purchased together at a discounted price.

This Report Includes...

• 84 customizable slides

• 54 graphs and charts

• Photographs of the disease and actual PsA patients

• Quotes from PsA patients

Click for table of contents and list of charts and graphs

Contents

• Section 1: Patients Understanding Psoriatic Arthritis: Focuses on patients and how they feel about their disease. Includes basic disease information, as well as epidemiology.

• Section 2: Perspectives Psoriatic Arthritis Management: A review of therapies, advantages and disadvantages, listing of major products and companies. Includes patient experience and insights on various therapies.

• Section 3: Potential Psoriatic Arthritis Market: Overall sales and prescription volume, growth rates and key products and companies provided. Includes pipeline products and market attractiveness assessment.

• Summary: The major take-aways from the presentation, including "What Makes the Psoriatic Arthritis Market Attractive," "Six Most Important Facts About the  PsA Market," "Patient Insights" and a statement from the National Psoriasis Foundation (NPF).

My first sign of psoriatic arthritis was soreness in my joints. It progressed to the point that every step was an effort – that’s the way it felt. You have to get treatment because you have to be able to get up and go. To get PsA under control you have to take more risks.

Patient perspective from slide #76       

It’s as easy as 1, 2, 3 with Psoriatic Arthritis Market Info. Insights on patients, doctors, treatment and market value are presented in an easy-to-follow format with current, reliable, referenced data.

Up to 30% of people with psoriasis also develop psoriatic arthritis, which causes pain, stiffness and swelling in and around the joints. While it is possible to have psoriatic arthritis without psoriasis, skin disease precedes joint disease in about 85% of patients. Psoriatic arthritis can develop at any time, but most commonly appears between the ages of 30 and 50 and affects men at a higher rate than women. Learn more about psoriatic arthritis, how it is diagnosed, the number of U.S. patients with PsA and how it affects their lives.

There is no specific test for psoriatic arthritis and the diagnosis is based on symptoms, examination, X-rays and eliminating other types of arthritis. There are 5 different forms of psoriatic arthritis which involve different joints and/or the spinal column. Treatment utilizes drugs in 3 main categories, including NSAIDs, DMARDs (disease modifying anti-rheumatic drugs) and biologics. PsA can be debilitating, both physically and psychologically, and can greatly affect patients’ emotional well-being. Both dermatologists and rheumatologists are involved in the diagnosis and treatment of the disease. Learn more about the different treatments, goals of therapy and how patients feel about the therapies.

The psoriatic arthritis market has experienced strong demand and is expected to continue to grow in future years due to the increased use of biologics and their associated costs. The market emerged with the launch of Amgen/Pfizer’s Enbrel® (etanercept) in 2002 as the first biologic therapy approved for psoriatic arthritis in both the United States and Canada. Since that time, more biologics have entered the market, including Abbott’s Humira® (adalimumab), another TNF (tumor necrosis factor) blocker, which was approved for psoriatic arthritis in 2005 and most recently, Centocor’s Simponi® (golimumab). Some companies have sought the psoriatic arthritis indication first since patients with psoriatic arthritis also suffer from psoriasis. Learn more about the biologics, new therapies and prescription volume from different treatments for psoriatic arthritis.

Drug Market Info provides a summary of why the PsA market is attractive. This overview summarizes all of the key points about this market in one easy slide so you can see what is needed and where a potential new therapy may fit. In addition, Drug Market Info summarizes the Six Most Important Facts you need to know about the PsA market.

Download 2012 Report: $4,950.00

Download 2011 Report: $3,950.00 – Save $1,000

Buy together with Psoriasis Market Info
and save $1,000!